ClinicalTrials.gg
CompletedNCT02178306ESPRITUpdated Jun 30, 2014

Efficacy and Safety of Telmisartan in Hypertensive Patients With Mild/Moderate or Severe Renal Impairment or Requiring Hemodialysis

A Phase 4 interventional study of Telmisartan low dose and Telmisartan high dose in Hypertension, sponsored by Boehringer Ingelheim. Completed. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2014-06-30.

Sponsored by Boehringer Ingelheim · Phase 4, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 4
Study type
Interventional
Enrollment
82
Allocation
Not applicable
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-19

Among 122 studies in Hypertension by Boehringer Ingelheim — 1 open to participants now, 1 under way, 1 of them phase 3. Hypertension · Boehringer Ingelheim.

Enrollment
61st of 74
82 · median 381
Started
2000
with 10 others
Phase 4
26 of 122
none open now
Registered
82nd of 122
by date

Among the 122 studies in Hypertension by Boehringer Ingelheim, this one is the 61st largest by enrollment of the 74 interventional ones that give a count, is one of 11 that started in 2000, is one of 26 in phase 4, and was the 82nd registered.

Hypertension

6,128 studies on the registry are indexed under Hypertension; 911 are open to participants now.

Browse Hypertension studies →

Open to participants now

1 of the 122 studies in Hypertension by Boehringer Ingelheim is open now, in 12 countries. Recruiting first, the newest first:

By country, each count listing its studies:

Who these studies take

Of the 556 Hypertension studies recruiting now, 262 (47%) set no upper age limit and 198 (36%) stop at 75 or younger; 40 take children under 18; 137 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 122 studies in Hypertension by Boehringer Ingelheim, or all of them as a file.
02

Study summary

To evaluate the safety and efficacy, in particular with regard to renal function of telmisartan at the doses of 40 mg and 80 mg in hypertensive patients with moderate to endstage renal impairment after 12 weeks of treatment

03

Conditions studied

  • Hypertension

Browse trials for

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Mild to moderate hypertension, sitting diastolic BP ≥ 90 mmHg and BP ≤ 109 mmHg at visit 2
  2. No increase of serum creatinine over 30% within 6 months before the trial
  3. Stable renal insufficiency with a serum creatinine between 200 and 600 µmol/l or maintenance of hemodialysis
  4. Stable proteinuria of at least 500 mg/24h
  5. No change in hemodialysis regimen within the last two months prior to visit 1
  6. 18 years of age or more
  7. Ability to provide written in accordance with good clinical practice and local registration
  8. Able to stop current antihypertensive therapy (ACE-Inhibitors or angiotensin II receptor subtype 1- Blocker) without risk to the patient

Exclusion criteria

Exclusion Criteria:

  1. Pre-menopausal women (last menstruation ≤ 1 year prior to start of run-in-phase) who:

    1. are not surgically sterile; and/or
    2. are nursing
    3. are of and are NOT practicing acceptable means of , do NOT plan to continue using this method throughout the study and do NOT agree to submit to periodic pregnancy testing during participation in studies of ≥ 3-months duration. Acceptable methods of birth control include oral, implantable or injectable contraceptives
  2. Known or suspected renovascular hypertension
  3. Mean sitting SBP ≥ 180 mmHg or mean sitting DBP ≥110 mmHg during any visit of the placebo run-in phase
  4. Hepatic dysfunction as defined by the following laboratory parameters:

    serum glutamate pyruvate transaminase () or serum glutamate oxaloacetate transaminase (AST) > than 2 times the

  5. Bilateral renal artery stenosis; renal artery stenosis in a solitary kidney, patients postrenal transplant or with only one kidney
  6. hypo- or hyperkalaemia
  7. Uncorrected volume depletion
  8. Uncorrected sodium depletion
  9. Primary aldosteronism
  10. Hereditary fructose intolerance
  11. Biliary obstructive disorders
  12. Patients who have previously experienced symptoms characteristic of angioedema during treatment with ACE inhibitors or angiotensin II antagonists
  13. History of drug or alcohol abuse within 6 months
  14. Chronic administration of any medications known to affect blood pressure, except medication allowed by the protocol (ß-blocker, alpha-blocker, calcium antagonists, clonidine, minoxidil, and diuretics)
  15. Any therapy within one month of signing the form
  16. Known to any component of the formulation
  17. Has no to a placebo run-in period (e.g. unstable angina within the past 3 months, stroke within the past 6 months or myocardial infarction or cardiac surgery within the past 3 months)
  18. Any other clinical condition which, in the opinion of the investigator, would not allow safe completion of the protocol and safe administration of telmisartan
  19. Compliance \< 70% during run-in period (defined by pill count)
  20. History of heart failure, , or any disorders requiring therapy
Terms in these criteria, in plain language(11)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

05

Study design

Phase
Phase 4
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
82 participants (actual)

Study arms

  • Experimental
    Telmisartan

    Drug: Telmisartan low dose · Drug: Telmisartan high dose · Drug: Placebo

Interventions

  • DrugTelmisartan low dose
  • DrugTelmisartan high dose

    patients switch to high dose if mean SBP \>= 85 mmHg after 4 weeks of treatment

  • DrugPlacebo

    Run-in phase

06

What researchers measure

Primary outcomes

  1. Changes from baseline in seated diastolic blood pressure (DBP) at trough

    Time frame: 12 weeks after start of treatment

Secondary outcomes

  1. Change from baseline in seated systolic blood pressure (SBP) at trough

    Time frame: 12 weeks after start of treatment

  2. Frequency of response categories of blood pressure

    Categories: 1. BP normal 2. DBP control 3. DBP response 4. SBP response 5. BP high normal

    Time frame: After 12 weeks of treatment

  3. Changes from baseline in proteinuria

    Time frame: 12 weeks after start of treatment

  4. Change in electrolyte excretion

    Time frame: 12 weeks after start of treatment

  5. Area under the telmisartan plasma concentration-time curve

    Time frame: Day 7 and 12 weeks after start of treatment

  6. Maximum plasma concentration (Cmax) of telmisartan

    Time frame: Day 7 and 12 weeks after start of treatment

  7. Time to peak (Tmax) plasma concentrations of telmisartan

    Time frame: Day 7 and 12 weeks after start of treatment

  8. Extent of protein binding of telmisartan

    equilibrium dialysis with subsequent determination of protein-bound telmisartan fraction

    Time frame: Day 7 and 12 weeks after start of treatment

07

Study locations

No study locations are listed for this record.

08

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Sep 2000 and a primary completion of Apr 2002. It does not say whether these dates are actual or estimated.

How these figures are worked out, and which studies are left out of them.

Registered
Jun 27, 2014
First posted
Jun 30, 2014
Start
Sep 2000
Primary completionActual
Apr 2002
Last update
Jun 30, 2014
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jun 30, 2014, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT02178306
Responsible party
Sponsor
First posted
Jun 30, 2014
Start date
Sep 2000
Primary completion
Apr 2002
Last update
Jun 30, 2014
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jun 2014. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion